Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...

BTIG downgraded AnaptysBio (ANAB) to Neutral from Buy without a price target The company’s topline data from the Phase 2b trial of ANB032 in atopic dermatitis are expected later in December and ...

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...